GeneDx Holdings (WGS) Stock Analysis & AI Equity Report
GeneDx Holdings (WGS) overview
GeneDx Holdings (WGS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 428m and operating profit of USD -13.1m; the year-end share price was 130.06 USD and market capitalisation was USD 3,804m. GeneDx Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get GeneDx Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About GeneDx Holdings
GeneDx provides clinical genetic testing and genomic interpretation, with a focus on rare and ultra-rare disorders. Its ExomeDx and GenomeDx tests support clinicians seeking diagnoses for patients, and its GeneDx Infinity dataset supports genomic discovery for biopharmaceutical companies. The company combines clinical expertise and technology to interpret genomic data and inform clinical decision-making.
Generate the GeneDx Holdings report
GeneDx Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for GeneDx Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on GeneDx Holdings
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.